1. Introduction
===============

Lung cancer is the leading cause of cancer-related deaths worldwide, and about 80% to 85% are diagnosed as non-small cell lung cancer (NSCLC).^\[[@R1],[@R2]\]^ Nearly, 30% to 40% of NSCLC patients are diagnosed with advanced or distant metastases at the time of diagnosis.^\[[@R3]\]^ A combination of platinum-based anticancer therapy is the standard regimen for these patients, while its response rate is only 30% to 40%.^\[[@R4]\]^ The resistance to standard first-line treatment is quickly developed,^\[[@R5]\]^ most patients finally develop into progressive-stage that result in requiring further therapies after the initial treatment.

Pemetrexed as a multi- targeted antifolate cytotoxic agent has reported superiority in targeting a variety of enzymes in the progression of pyrimidine and purine synthesis, which was also accepted its use in the therapy of advanced NSCLC who has failed the prior platinum-based anticancer therapy because of its favorable safety profile and relatively good efficacy.^\[[@R6]\]^

In addition, NSCLC is considered as a highly heterogeneous disease on gene level, within the various subtypes,^\[[@R7]\]^ introducing molecular targeted drugs could be approved to treat the subgroup of cancer patients for whom develop progressive after the failure of initial therapy.^\[[@R5]\]^ Developments in genetic discoveries have proved that epidermal growth factor receptor (EGFR) -dependent pathway is effective in most of NSCLC patients and it has important effect on in the progression of epithelial cells.^\[[@R8]\]^

Gefitinib, one of the first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), has been accepted by National Comprehensive Cancer Network (NCCN) guidelines to treat NSCLC.^\[[@R9]\]^ Relevant articles have been designed to explore its safety and effectiveness, and reported a superiority for second-line therapy.^\[[@R8]\]^

Previously, there are randomized controlled trials assessing the effect of pemetrexed compared with gefitinib in a second-line therapy setting with different results. There are still conflicting results because of their side effects or lack of therapeutic effectiveness or both pemetrexed and gefitinib are limited to tumors with specific genetic alterations.^\[[@R10]\]^ Our meta-analysis aims to assess the effectiveness and safety of pemetrexed versus gefitinib in pre-treated NSCLC.

2. Methods and materials
========================

2.1. Search strategy
--------------------

Pubmed, Embase, Cochrane library were performed to identify the eligible studies up to September 2019. The literature search process was established with the keywords and relevant Medical Subject Heading (MeSH) terms: "non small cell lung cancer" AND "pemetrexed" AND "gefitinib", AND "pretreated patients." The reference lists were also hand-searched to check for additional relevant articles.

2.2. Eligibility criteria
-------------------------

Researches were included in the current study should meet the following criteria:

1.  the studies are designed as random control trials (RCTs);

2.  all patients are NSCLC patients treated with pemetrexed therapy as compared to gefitinib;

3.  patient harboring treatment-refractory who fail the prior therapy;

4.  the interested outcomes were survival efficacy and adverse effects;

5.  the full-text papers were only included.

Publications with the following exclusion criteria were excluded:

1.  articles are not designed as RCT;

2.  the reported data was insufficient;

3.  case reports, or observational literature;

4.  duplicated previous researches.

2.3. Quality assessment and data extraction
-------------------------------------------

Two authors independently assessed the quality of the retrieved trials. Study quality was justified using the Jadad scale.^\[[@R11]\]^ Two investigators separately carried out the relevant data from each article independently. Disagreement was revolved by consensus. We extracted the main contents based on the following: family name of the first author, the year of the publication, country, number of patients, mean age, and end-point of interested.

2.4. Statistical analysis
-------------------------

We extracted the corresponding odds ratios (ORs) to describe the interested outcomes, including survival and dichotomous data, respectively, with corresponding 95% confidence intervals (CIs). The statistical analyses were conducted using Review Manager version 5.3 software (Revman; The Cochrane collaboration Oxford, United Kingdom). The heterogeneity across studies was using the I^2^ statistic.^\[[@R12]\]^ I^2^ value \>50% recognized as the high degree of heterogeneity.^\[[@R13]\]^ When there was high degree of heterogeneity among articles, the random-effects model was used. Otherwise, we choose the fixed effects model. A *P* value less than .05 was suggested as statistically significant difference. Results of our meta-analysis were shown in forest plots.

3. Results
==========

3.1. Overview of literature search and general features of the studies
----------------------------------------------------------------------

In all, 267 studies were included originally. Based on the review of the abstracts and titles, 10 publications were evaluated in more detail, but some did not provide enough detail of results of 2 groups. Finally, a total of 5 RCTs^\[[@R14]--[@R18]\]^ assess the impact of pemetrexed versus gefitinib. The search process is described in Figure [1](#F1){ref-type="fig"}.

![PRISMA flow chart of selection process to identify studies eligible for pooling.](medi-99-e21170-g001){#F1}

All included trials in our analysis were based on moderate to high quality evidence. Table [1](#T1){ref-type="table"} provided a brief description of these 5 studies.
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3.2. Clinical and methodological heterogeneity
----------------------------------------------

Pooled analysis of PFS comparing pemetrexed versus gefitinib

The pooled data showed that there is no benefit between pemetrexed and gefitinib in terms of the PFS (OR = 1.17, 95%CI = 0.60--2.30, I^2^ = 93%, *P* = .65) (Fig. [2](#F2){ref-type="fig"}). While, subgroup analyses by the EGFR mutation-type indicated that the comparison of gefitinib therapy versus pemetrexed did show PFS benefit 0.35 (95% CI 0.12--1.01, I^2^ = 81%, *P* = .05) (Fig. [3](#F3){ref-type="fig"}) among EGFR mutation-positive patients, whereas in EGFR wild-type subgroup the PFS was similar between 2 groups (OR = 0.83, 95%CI = 0.31--2.24, I^2^ = 84%,*P* = .72) (Fig. [4](#F4){ref-type="fig"}).

![Pooled analysis of progression-free survival comparing pemetrexed versus gefitinib.](medi-99-e21170-g003){#F2}

![Pooled analysis of progression-free survival comparing pemetrexed versus gefitinib in epidermal growth factor receptor mutation-positive subgroup.](medi-99-e21170-g004){#F3}

![Pooled analysis of progression-free survival comparing pemetrexed versus gefitinib in epidermal growth factor receptor wild-type subgroup.](medi-99-e21170-g005){#F4}

Pooled analysis of OS comparing pemetrexed versus gefitinib.

Pooling the OS data from 4 articles revealed that pemetrexed did not prolong the OS (OR = 0.97, 95%CI = 0.77--1.21, I^2^ = 17%, *P* = .76) than the gefitinib group (Fig. [5](#F5){ref-type="fig"}).

![Pooled analysis of overall survival comparing pemetrexed versus gefitinib.](medi-99-e21170-g006){#F5}

Pooled analysis of objective response rate (ORR) comparing pemetrexed versus gefitinib.

The pooled data showed that there is no advantage of ORR between 2 arms (OR = 0.84, 95%CI = 0.34--2.05, I^2^ = 80%, *P* = .70). In other words, neither pemetrexed nor gefitinib increased the rate of ORR (Fig. [6](#F6){ref-type="fig"}).

![Pooled analysis of objective response rate comparing pemetrexed versus gefitinib.](medi-99-e21170-g007){#F6}

Pooled analysis of SAE comparing pemetrexed versus gefitinib.

We define the grade 3/4 toxicities as severe adverse effects (SAEs). In the analysis of thrombocytopenia (OR = 1.34, 95%CI = 0.33--5.43, I^2^ = 25%,*P* = .68), anemia (OR = 2.25, 95%CI = 0.63--8.09, I^2^ = 11%,*P* = .21), fatigue (OR = 1.02, 95%CI = 0.38--2.69, I^2^ = 0%,*P* = .97) and rash (OR = 0.42, 95%CI = 0.04--4.05, I^2^ = 66%,*P* = .45) were included, and the data are shown in Figures [7](#F7){ref-type="fig"}--[10](#F10){ref-type="fig"}. However, all above pooling analysis does not reach a statistically significant level (*P* \> .05).

![Pooled analysis of thrombocytopenia comparing pemetrexed versus gefitinib.](medi-99-e21170-g008){#F7}

![Pooled analysis of anemia comparing pemetrexed versus gefitinib.](medi-99-e21170-g009){#F8}

![Pooled analysis of fatigue comparing pemetrexed versus gefitinib.](medi-99-e21170-g010){#F9}

![Pooled analysis of rash comparing pemetrexed versus gefitinib.](medi-99-e21170-g011){#F10}

4. Discussion
=============

NSCLC is the common malignancy worldwide. Despite new therapies improved the survival of advanced NSCLC patients, few effective treatment options have emerged to treat NSCLC, especially for patients who failed the initial therapy.^\[[@R19]\]^

Pemetrexed is a multi-targeted antifolate (MTA) and exerts its antitumor activity by inhibiting the replication process folate metabolism. The pemetrexed can suppress several key enzymes result in reducing the rate of drug- resistant tumors, which makes it achieve superior efficacy than traditional antifolate chemotherapy. Pemetrexed has been accepted using as a second-line treatment for advanced NSCLC by FDA.^\[[@R17]\]^ Gefitinib is an EGFR-targeted agent. Previous articles have reported that gefitinib has selected as therapeutic option in pre-treated NSCLC.

Recent clinical trials respectively assess the effect of gefitinib compared with pemetrexed as a second-line therapy setting for NSCLC patients. However, the conclusions remain controversial. Thus, it is very necessary to identify an efficient and tolerable adverse effects maintenance therapy option to achieve survival and toxicity profile benefit for advanced lung cancer patients.^\[[@R17]\]^

In this study, our analysis demonstrated the maintenance effectiveness and toxicity profile of pemetrexed versus gefitinib. However, subgroups analysis revealed that EGFR mutation-positive subgroup did improved PFS from gefitinib than pemetrexed. It demonstrated that the superiority of gefitinib was associated with genetic characteristics between arms.

The evidences demonstrating survival efficacy of gefitinib treatment in a subgroup analysis of INFORM and SATURN study was better than placebo with EGFR mutation-positive patients, while similar survival efficacy compared with placebo for EGFR wild-type patients in maintenance treatment.^\[[@R20],[@R21]\]^ Previous phase III trials have demonstrated that gefitinib was the favored choice in second-line therapy for patients with mutation-positive when compared with pemetrexed single agent;^\[[@R16]\]^ in contrast, EGFR wild-type patients achieved better efficacy with pemetrexed.^\[[@R14],[@R18]\]^ Even though, the prolongation of PFS did not associate with the difference of OS, which was probably due to treatment crossover at the progression.

These findings suggest that decisions making for the second-line therapy should be done with the knowledge of genotype mutational status. In our meta-analysis, there is no significant difference of efficacy between pemetrexed and gefitinib for EGFR wild-type patients. This result might be derived from a small number of enrolled patients in EGFR wild-type subgroup, which can be considered statistical significance when clinically sample size is sufficient.

In terms of the toxicities, previous studies have indicated that the adverse effects of the 2 groups were somewhat different, but were all mild and well tolerated, which was consistent with our finding.^\[[@R20],[@R22],[@R23]\]^ This result demonstrated that the systematically established management of adverse events used in this therapy could be accepted as an effective treatment for patients on therapy to achieve the maximum benefit from drugs. Given the different toxicity profiles of pemetrexed or gefitinib, a key factor to select therapy should be patients' comorbidities and tolerance of expected tumor-related side effects.

Even though, all included studies are designed as RCTs, imbalance in experimental design and clinical characteristics, bias still exist, and this may have effect on the findings of our analysis. So, it indicated that more large-scale, high-quality studies with greater statistical power are required to verify the clinical efficacy of pemetrexed and gefitinib.

5. Conclusion
=============

Our study showed that pemetrexed was not associated with survival benefit than gefitinib therapy among pre-treated NSCLC patients. However, gefitinib showed superior PFS efficacy than pemetrexed for EGFR mutation-type patients. Moreover, pemetrexed had no significantly favorable safety profile, as compared with gefitinib. Future investigations are required to identify relevant biomarkers in selected patients that would most likely benefit from pemetrexed or gefitinib treatment in pre-treated advanced NSCLC patients.
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